| Reference |
|---|
Jardim Perassi B, Irrera P, Oluwatola O, Abrahams D, Estrella V, Ordway B, et al. L-DOS47 Elevates Pancreatic Cancer Tumor pH and Enhances Response to Immunotherapy. Biomedicines. 2024;12: pubmed publisher |
Noe P, Wang J, Chung K, Cheng Z, Field J, Shen X, et al. Therapeutically targeting type I interferon directly to XCR1+ dendritic cells reveals the role of cDC1s in anti-drug antibodies. Front Immunol. 2023;14:1272055 pubmed publisher |
Li W, Zhao C, Li W, Gong Y, Ma K, Lu Y, et al. BRAF D594A mutation defines a unique biological and immuno-modulatory subgroup associated with functional CD8+ T cell infiltration in colorectal cancer. J Transl Med. 2023;21:737 pubmed publisher |
Linnerbauer M, Beyer T, Nirschl L, Farrenkopf D, L xf6 xdf lein L, Vandrey O, et al. PD-L1 positive astrocytes attenuate inflammatory functions of PD-1 positive microglia in models of autoimmune neuroinflammation. Nat Commun. 2023;14:5555 pubmed publisher |
Chen Y, Li J, Pu L, Hu J, Fang L, Zhou F, et al. DNAJB4 suppresses breast cancer progression and promotes tumor immunity by regulating the Hippo signaling pathway. Discov Oncol. 2023;14:144 pubmed publisher |
Xu S, Cai J, Cheng H, Wang W. Sustained release of therapeutic gene by injectable hydrogel for hepatocellular carcinoma. Int J Pharm X. 2023;6:100195 pubmed publisher |
Blangero F, Robert M, Andraud T, Dumontet C, Vidal H, Eljaafari A. Contribution of Mesenchymal Stem Cells from Obese Adipose Tissue to PD-L1 Over-Expression and Breast Cancer Progression through Pathogenic Th17 Cell Activation. Cancers (Basel). 2023;15: pubmed publisher |
Zhang G, Lan B, Zhang X, Lin M, Liu Y, Chen J, et al. AR-A014418 regulates intronic polyadenylation and transcription of PD-L1 through inhibiting CDK12 and CDK13 in tumor cells. J Immunother Cancer. 2023;11: pubmed publisher |
Ren J, Han X, Lohner H, Hoyle R, Li J, Liang S, et al. P. gingivalis Infection Upregulates PD-L1 Expression on Dendritic Cells, Suppresses CD8+ T-cell Responses, and Aggravates Oral Cancer. Cancer Immunol Res. 2023;11:290-305 pubmed publisher |
Ebelt N, Manuel E. 5-Azacytidine-Mediated Modulation of the Immune Microenvironment in Murine Acute Myeloid Leukemia. Cancers (Basel). 2022;15: pubmed publisher |
Mao M, Chen Y, Yang J, Cheng Y, Xu L, Ji F, et al. Modification of PLAC8 by UFM1 affects tumorous proliferation and immune response by impacting PD-L1 levels in triple-negative breast cancer. J Immunother Cancer. 2022;10: pubmed publisher |
Shen S, Li Y, Jin M, Fan D, Pan R, Lin A, et al. CD4+ CTLs Act as a Key Effector Population for Allograft Rejection of MSCs in a Donor MHC-II Dependent Manner in Injured Liver. Aging Dis. 2022;13:1919-1938 pubmed publisher |
Zhang X, Halberstam A, Zhu W, Leitner B, Thakral D, Bosenberg M, et al. Isotope tracing reveals distinct substrate preference in murine melanoma subtypes with differing anti-tumor immunity. Cancer Metab. 2022;10:21 pubmed publisher |
Zhao W, Wu Y, Zhao F, Xue Z, Liu W, Cao Z, et al. Scoring model based on the signature of non-m6A-related neoantigen-coding lncRNAs assists in immune microenvironment analysis and TCR-neoantigen pair selection in gliomas. J Transl Med. 2022;20:494 pubmed publisher |
Davies J, Karimipour F, Zhang L, Nagarsheth N, Norberg S, Serna C, et al. Non-synergy of PD-1 blockade with T-cell therapy in solid tumors. J Immunother Cancer. 2022;10: pubmed publisher |
El Sayes N, Walsh S, Vito A, Reihani A, Ask K, Wan Y, et al. IFNAR blockade synergizes with oncolytic VSV to prevent virus-mediated PD-L1 expression and promote antitumor T cell activity. Mol Ther Oncolytics. 2022;25:16-30 pubmed publisher |
Wang X, Chen Y, Lan B, Wang Y, Lin W, Jiang X, et al. Heterogeneity of tyrosine-based melanin anabolism regulates pulmonary and cerebral organotropic colonization microenvironment of melanoma cells. Theranostics. 2022;12:2063-2079 pubmed publisher |
Hagemans I, Wierstra P, Steuten K, Molkenboer Kuenen J, van Dalen D, ter Beest M, et al. Multiscale imaging of therapeutic anti-PD-L1 antibody localization using molecularly defined imaging agents. J Nanobiotechnology. 2022;20:64 pubmed publisher |
Yang K, Choi C, Cho H, Ahn W, Kim S, Shin S, et al. Antigen-Capturing Mesoporous Silica Nanoparticles Enhance the Radiation-Induced Abscopal Effect in Murine Hepatocellular Carcinoma Hepa1-6 Models. Pharmaceutics. 2021;13: pubmed publisher |
Xiang H, Chan A, Ahene A, Bellovin D, Deng R, Hsu A, et al. Preclinical characterization of bemarituzumab, an anti-FGFR2b antibody for the treatment of cancer. MAbs. 2021;13:1981202 pubmed publisher |
Yang Z, Xu G, Wang B, Liu Y, Zhang L, Jing T, et al. USP12 downregulation orchestrates a protumourigenic microenvironment and enhances lung tumour resistance to PD-1 blockade. Nat Commun. 2021;12:4852 pubmed publisher |
Ebelt N, Zamloot V, Zuniga E, Passi K, Sobocinski L, Young C, et al. Collagenase-Expressing Salmonella Targets Major Collagens in Pancreatic Cancer Leading to Reductions in Immunosuppressive Subsets and Tumor Growth. Cancers (Basel). 2021;13: pubmed publisher |
Sun Y, Jing J, Xu H, Xu L, Hu H, Tang C, et al. N-cadherin inhibitor creates a microenvironment that protect TILs from immune checkpoints and Treg cells. J Immunother Cancer. 2021;9: pubmed publisher |
Eissa I, Mukoyama N, Abdelmoneim M, Naoe Y, Matsumura S, Bustos Villalobos I, et al. Oncolytic herpes simplex virus HF10 (canerpaturev) promotes accumulation of CD8+ PD-1- tumor-infiltrating T cells in PD-L1-enriched tumor microenvironment. Int J Cancer. 2021;149:214-227 pubmed publisher |
Fang W, Zhou T, Shi H, Yao M, Zhang D, Qian H, et al. Progranulin induces immune escape in breast cancer via up-regulating PD-L1 expression on tumor-associated macrophages (TAMs) and promoting CD8+ T cell exclusion. J Exp Clin Cancer Res. 2021;40:4 pubmed publisher |
Ferrere G, Tidjani Alou M, Liu P, Goubet A, Fidelle M, Kepp O, et al. Ketogenic diet and ketone bodies enhance the anticancer effects of PD-1 blockade. JCI Insight. 2021;6: pubmed publisher |
Yoo G, Ahn W, Kim S, Kang W, Choi C, Park H. Radiation-induced abscopal effect and its enhancement by programmed cell death 1 blockade in the hepatocellular carcinoma: A murine model study. Clin Mol Hepatol. 2021;27:144-156 pubmed publisher |
Gao H, Wu Y, Shi J, Zhang X, Liu T, Hu B, et al. Nuclear imaging-guided PD-L1 blockade therapy increases effectiveness of cancer immunotherapy. J Immunother Cancer. 2020;8: pubmed publisher |
Wu B, Chiang H, Sun X, Yuan B, Mitra P, Hu Y, et al. Genetic ablation of adipocyte PD-L1 reduces tumor growth but accentuates obesity-associated inflammation. J Immunother Cancer. 2020;8: pubmed publisher |
Liu Y, Gao Y, Hao H, Hou T. CD279 mediates the homeostasis and survival of regulatory T cells by enhancing T cell and macrophage interactions. FEBS Open Bio. 2020;10:1162-1170 pubmed publisher |
Neuwelt A, Kimball A, Johnson A, Arnold B, Bullock B, Kaspar R, et al. Cancer cell-intrinsic expression of MHC II in lung cancer cell lines is actively restricted by MEK/ERK signaling and epigenetic mechanisms. J Immunother Cancer. 2020;8: pubmed publisher |
Zhang J, Yamada O, Kida S, Murase S, Hattori T, Oshima Y, et al. Downregulation of PD-L1 via amide analogues of brefelamide: Alternatives to antibody-based cancer immunotherapy. Exp Ther Med. 2020;19:3150-3158 pubmed publisher |
Shen M, Xu Z, Xu W, Jiang K, Zhang F, Ding Q, et al. Inhibition of ATM reverses EMT and decreases metastatic potential of cisplatin-resistant lung cancer cells through JAK/STAT3/PD-L1 pathway. J Exp Clin Cancer Res. 2019;38:149 pubmed publisher |
Zhou Z, Chen H, Xie R, Wang H, Li S, Xu Q, et al. Epigenetically modulated FOXM1 suppresses dendritic cell maturation in pancreatic cancer and colon cancer. Mol Oncol. 2019;13:873-893 pubmed publisher |
Zamarin D, Ricca J, Sadekova S, Oseledchyk A, Yu Y, Blumenschein W, et al. PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy. J Clin Invest. 2018;128:1413-1428 pubmed publisher |
